Biocon unveils Tacrolimus capsules in US
Bengaluru and Iselin: Biocon Ltd, has recently announced the launch of Tacrolimus capsules in the US.
Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body's ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades.
The launch of Tacrolimus capsules, following an approval from the US FDA in November 2020, underscores Biocon's relentless pursuit of its mission to make affordable healthcare accessible.
Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, said: "The launch of Tacrolimus capsules in the US is another milestone for Biocon that reflects our commitment to continually evaluate and expand our portfolio of complex products to serve patients."
Biocon Limited is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases.
The company has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe.